Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
2
×
Tags
biotech
boston
2
×
boston blog main
boston top stories
eli lilly
2
×
indiana blog main
2
×
indiana top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
alexion pharmaceuticals
alnylam pharmaceutials
arrowhead pharmaceuticals
avapritinib
blueprint medicines
boehringer ingelheim
cancer
cancer drugs
capmatinib
clinical trials
deals
dicerna pharmaceuticals
europe blog main
europe top stories
gastrointestinal stromal tumors
genentech
hepatitis b
johnson & johnson
life science
medullary thyroid cancer
neurodegenerative diseases
non-small cell lung cancer
novartis
pralsetinib
primary hyperoxaluria
rna interference
roche
selpercatinib
What
medicines
2
×
abandoning
address
ago
approval
approves
baggage
blueprint
cancer
carries
certain
companies
cuts
deal
designed
development
dicerna
drug
fda
free
genetic
gets
interference
latest
long
pass
pharma
ret
rna
rnai
signature
signatures
signs
small
targeted
targeting
therapy
wasn’t
Language
unset
Current search:
medicines
×
photo
×
boston
×
" eli lilly "
×
" indiana blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M